Original language | English |
---|---|
Pages (from-to) | 1172-1177 |
Number of pages | 6 |
Journal | Haematologica |
Volume | 106 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2021 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma. / Watanabe, Keiichiro; Bat-Erdene, Ariunzaya; Tenshin, Hirofumi et al.
In: Haematologica, Vol. 106, No. 4, 04.2021, p. 1172-1177.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
AU - Watanabe, Keiichiro
AU - Bat-Erdene, Ariunzaya
AU - Tenshin, Hirofumi
AU - Cui, Qu
AU - Teramachi, Jumpei
AU - Hiasa, Masahiro
AU - Oda, Asuka
AU - Harada, Takeshi
AU - Miki, Hirokazu
AU - Sogabe, Kimiko
AU - Oura, Masahiro
AU - Sumitani, Ryohei
AU - Mitsui, Yukari
AU - Endo, Itsuro
AU - Tanaka, Eiji
AU - Kawatani, Makoto
AU - Osada, Hiroyuki
AU - Matsumoto, Toshio
AU - Abe, Masahiro
N1 - Funding Information: this work was supported in part by JSPS KAKENHI grant ns. JP15K20536, JP16K11504, JP17KK0169, JP17K09956, JP17H05104, JP18K08329, JP18K16118, and JP18H06294, and the Research Clusters program of Tokushima University. The funders had no role in study design, data collection and analysis, the decision to publish or the preparation of the manuscript. The authors would like to thank Dr. Toshihiko Nogawa (RIKEN) for preparing reveromycin A. Funding Information: Contributions: KW, AB, HT, MK, HO and MA designed the research and conceived the project. Animal experiments were performed by KW, QC, HT, TH, HM, KS, MO, RS and JT; cell cultures by KW, AB, HT, AO, TH, KS, MO and RS; immunoblotting by AB, JT, HT, AO and MH; and bone analyses by KW, QC, YM, MH, IE, and ET. KW, AB, HT, MK, HO, TM and MA analyzed and discussed the data, and wrote the manuscript. Funding: this work was supported in part by JSPS KAKENHI grant ns. JP15K20536, JP16K11504, JP17KK0169, JP17K09956, JP17H05104, JP18K08329, JP18K16118, and JP18H06294, and the Research Clusters program of Tokushima University. The funders had no role in study design, data collection and analysis, the decision to publish or the preparation of the manuscript. The authors would like to thank Dr. Toshihiko Nogawa (RIKEN) for preparing reveromycin A.
PY - 2021/4
Y1 - 2021/4
UR - http://www.scopus.com/inward/record.url?scp=85103682696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103682696&partnerID=8YFLogxK
U2 - 10.3324/haematol.2019.244418
DO - 10.3324/haematol.2019.244418
M3 - Letter
C2 - 32586903
AN - SCOPUS:85103682696
SN - 0390-6078
VL - 106
SP - 1172
EP - 1177
JO - Haematologica
JF - Haematologica
IS - 4
ER -